TopDollar Investing

[Slimer84]

Bohai Pharmaceuticals Announces Availability of SmallcapInsights.com Article

Industry Veteran Dr. John Faessel Discusses Bohai's Developments in
the Traditional Chinese Medicine Industry and Its Recently Reported
Record FY 2010 Numbers
Sep. 30, 2010 (Business Wire) -- Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announces the release of a SmallcapInsights.com article by industry veteran Dr. John Faessel.

Entitled “A Best China Mini-Cap Idea for 2011”, Dr. Faessel discusses Bohai’s participation in the Traditional Chinese Medicine industry in China, including recent developments such as Bohai’s 5 new product introductions in 2010, its recent research coverage by Murphy Analytics, and its just released financial numbers for the fiscal year ended June 30, 2010, which were record results.

In addition, the article provides an overview of Bohai’s business model, and its growth potential going forward.

From the article, Dr. Faessel states, “The [Chinese] government wants to have more than 90% of its population covered by some sort of basic medical insurance by 2011. Bottom line, to the Chinese consumer this means that 80 to 90% of the cost of medicines and pharmaceuticals will now be paid by the government in reimbursements. Obviously this has huge implications for BOPH.”

The article details the significant growth projected in China’s pharmaceutical market, which benefits from a growing elderly population, a PRC government that is increasing government healthcare spending to approximately $125 billion by 2011, and direct health care subsidies for urban and rural residents in excess of $57 billion.

The article may be viewed at www.smallcapinsights.com.

About Bohai Pharmaceuticals Group, Inc.

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH) is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on Traditional Chinese Medicine in China. Bohai’s medicines address common health problems such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. Bohai’s products are sold either by prescription through hospitals or over-the-counter through local pharmacies and retail drug store chains. Bohai has approximately 600 employees, including approximately 300 sales representatives, operating from 20 offices throughout China. Bohai’s lead products, Tongbi Capsules and Tablets and Lung Nourishing Cream, are eligible for reimbursement under China’s National Medical Insurance Program.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Investor Relations Portal, Investor Fact Sheet and Overview Video.

For additional information, please visit Bohai’s corporate website: www.bohaipharma.com.

Additional Information Relating to Bohai’s Trading Data

Due to certain recent disruptions in the marketplace relating to quotations on the OTC Bulletin Board operated by FINRA (OTCBB), incomplete trading data may exist for certain companies like Bohai. Real-time trading data for Bohai on the OTCQB market is available through the below link. Readers are advised that OTCQB market is operated by the owner of otcmarkets.com, and Bohai Pharmaceuticals Group, Inc. makes no representation or warranty regarding the OTCQB market.

For real-time trading data for Bohai on the OTCQB market, including Level 2 quotes, please visit: www.otcmarkets.com/stock/boph/quote.

SEC Section 17(b) Disclosure

SmallcapInsights.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. (“Trilogy”). Trilogy has been engaged by Bohai Pharmaceuticals Group, Inc. ("BOPH") to provide investor relations services for compensation of a monthly retainer in the amount of $12,500. Trilogy Capital Partners owns 31,250 shares of the Common Stock of BOPH. In addition, Alfonso J. Cervantes, the principal of Trilogy, beneficially owns 90,000 shares of the Common stock of BOPH through La Mancha Capital Group, LLC, a limited liability company and is a non-managing member of Regeneration Capital Group, LLC, which owns 541,875 shares of the Common Stock of BOPH.

Although the article described herein was commissioned and paid for by Bohai Pharmaceuticals Group, Inc., the company notes that the article was generated independently by the author, and statements by the author are his own and not attributable to Bohai Pharmaceuticals Group, Inc. Readers are advised to review the article in its entirety, including the disclosures and disclaimers noted therein.

Cautionary Note Regarding Forward Looking Statements

This press release, the article referred to herein and the statements of representatives of Bohai Pharmaceuticals Group, Inc. (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the Securities and Exchange Commission (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.




Company Contact:

Bohai Pharmaceuticals Group, Inc.

Gene Hsiao, Chief Financial Officer

212-521-4470

or

Financial Communications Contact:

Trilogy Capital Partners - Asia

Darren Minton, President

Toll-free: 800-592-6067

[e-mail]






Source: Business Wire (September 30, 2010 - 6:25 PM EDT)

News by QuoteMedia
www.quotemedia.com